Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouattour, Mohamed, Soubrane, Olivier, de Gramont, Armand, Faivre, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225/
https://www.ncbi.nlm.nih.gov/pubmed/27887632
http://dx.doi.org/10.1186/s13063-016-1675-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225/
https://www.ncbi.nlm.nih.gov/pubmed/27887632
http://dx.doi.org/10.1186/s13063-016-1675-8

Ejemplares similares